Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Linear regression analysis of S100A9 in 138 rheumatoid arthritis (RA) patients

From: Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis

Variable β SE t Pvalue 95% Confidence interval
Univariate analysis:      
   ACPA 0.41 0.21 1.91 0.06 -0.01 to 0.83
   Body mass indexa 0.86 0.47 1.84 0.07 -0.07 to 1.78
   Diastolic blood pressure 0.02 0.01 1.69 0.09 -0.003 to 0.04
   Carriage of PTPN22 Cys1858Thr 0.52 0.24 2.11 0.04 0.03 to 1.00
   sRAGEa -0.39 0.20 -1.94 0.06 -0.78 to 0.009
   S100A8a 0.20 0.06 3.65 < 0.001 0.09 to 0.31
   S100A12a 0.54 0.10 5.46 < 0.001 0.34 to 0.73
Multivariate analysis:      
   Body mass indexa 0.86 0.41 2.10 0.04 0.05 to 1.67
   S100A8a 0.11 0.05 2.05 0.04 0.003 to 0.22
   S100A12a 0.46 0.10 4.50 < 0.001 0.26 to 0.67
  1. Variables that were not listed in the simple and multiple linear regression models did not achieve P < 0.1. Adjusted R2 of the multiple linear regression model = 0.25.
  2. aLogarithmic (base e) transformation; S100A9 was logarithmically (base e) transformed.
  3. ACPA, anti-citrullinated peptide antibodies; PTPN22, protein tyrosine phosphatase, non-receptor type 22; sRAGE, soluble receptor for advanced glycation end products.